EXtended Therapy in Genotype 3 Infected Patients Who do Not AChieve a Treatment Response at Week 4 (RVR) But do Achieve a Complete Early Virologic Response (cEVR).

Trial Profile

EXtended Therapy in Genotype 3 Infected Patients Who do Not AChieve a Treatment Response at Week 4 (RVR) But do Achieve a Complete Early Virologic Response (cEVR).

Discontinued
Phase of Trial: Phase III

Latest Information Update: 28 Sep 2011

At a glance

  • Drugs Peginterferon alfa-2b; Ribavirin
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Acronyms EXACT-R(3)
  • Most Recent Events

    • 28 Sep 2011 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 28 Sep 2011 Planned end date changed from 1 Aug 2015 to 1 Jun 2011 as reported by ClinicalTrials.gov.
    • 03 Apr 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top